Cargando…
Targeted agents for patients with advanced/metastatic pancreatic cancer: A protocol for systematic review and network meta-analysis
BACKGROUND: Pancreatic cancer (PC) is a devastating malignant tumor. Although surgical resection may offer a good prognosis and prolong survival, approximately 80% patients with PC are always diagnosed as unresectable tumor. National Comprehensive Cancer Network's (NCCN) recommended gemcitabine...
Autores principales: | Di, Baoshan, Pan, Bei, Ge, Long, Ma, Jichun, Wu, Yiting, Guo, Tiankang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895402/ https://www.ncbi.nlm.nih.gov/pubmed/29595634 http://dx.doi.org/10.1097/MD.0000000000010115 |
Ejemplares similares
-
Adjuvant targeted therapy combined with surgery for advanced and metastatic renal cell carcinoma: A protocol for systematic review and meta analysis
por: Jin, Hongyu, et al.
Publicado: (2021) -
A comprehensive assessment of single nucleotide polymorphisms associated with pancreatic cancer risk: A protocol for systematic review and network meta-analysis
por: Ye, Zhuo-Miao, et al.
Publicado: (2020) -
Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer
por: Chen, Zhiliang, et al.
Publicado: (2021) -
S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials
por: Zhong, Sheng, et al.
Publicado: (2017) -
A systematic review and network meta-analysis protocol of neoadjuvant treatments for patients with gastric cancer
por: Long, Bo, et al.
Publicado: (2018)